Epidemiology of ventilator-associated pneumonia in ICU COVID-19 patients: an alarming high rate of multidrug-resistant bacteria.
Nardi TetajAlessandro CaponeGiulia Valeria StaziMaria Cristina MariniGabriele GarottoDonatella BussoSilvana ScarciaIlaria CaravellaManuela MacchioneGiada De AngelisRachele Di LorenzoAlessandro CarucciMaria Vittoria AntonicaIlaria GavianoCarlo InversiElisabetta AgostiniFlaminia CanichellaGiorgia TaloniFrancesca EvangelistaIlaria OnnisGiulia MogaveroMaria Elena LamannaDorotea RubinoMattia Di FrischiaCandido PorcelliElena CesiAndrea AntinoriFabrizio PalmieriGianpiero D'OffiziFabrizio TagliettiCarla NisiiMaria Adriana CataldoStefania IannielloPaolo CampioniFrancesco VaiaEmanuele NicastriEnrico GirardiLuisa Marchioninull nullPublished in: Journal of Anesthesia, Analgesia and Critical Care (Online) (2022)
COVID-19 patients have a higher incidence of VAP compared to the general ICU population, but it is similar to that of ICU ARDS patients in the pre-COVID-19 period. Interleukin-6 inhibitors and blood transfusions may increase the risk of VAP. The widespread use of empirical antibiotics in these patients should be avoided to reduce the selecting pressure on the growth of multidrug-resistant bacteria by implementing infection control measures and antimicrobial stewardship programs even before ICU admission.
Keyphrases
- multidrug resistant
- intensive care unit
- end stage renal disease
- sars cov
- mechanical ventilation
- newly diagnosed
- ejection fraction
- chronic kidney disease
- coronavirus disease
- prognostic factors
- public health
- peritoneal dialysis
- acute respiratory distress syndrome
- patient reported outcomes
- gram negative
- escherichia coli
- cystic fibrosis
- pseudomonas aeruginosa
- patient reported